The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
The First Affiliated Hospital with Nanjing Medical University
Phase
Observational
Started
2024-03-01
Last updated
2024-03-28
Condition(s) studied
Social IsolationSCDSubjective Cognitive DeclineMCIMild Cognitive ImpairmentADAlzheimer Disease
Investigational drug(s) / intervention(s)
social isolation
social isolation: social isolation (0≤LSNS-6≤12)
Study summary
The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD
1. To explore the association between social isolation and lonely SCD populations and the occurrence and progression of MCI and AD through cross-sectional studies, cohort studies and randomized controlled trials of SCD;
2. To clarify the correlation between different carrier states, resting brain function connectivity characteristics, and dual-task walking ability of APOEε4 allele and the progression of SCD to MCI and AD during the cognitive progress of people with SCD affected by social isolation;
3. Establish a predictive model of cognitive decline from SCD to MCI and AD, and apply it to the SCD population to carry out individualized interventions;
4. Confirm the protective effect of social interaction on cognitive level and brain function in SCD patients.
Eligibility
Sex
ALL
Min age
45 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* SCD
1. Self-perceived continuous cognitive decline compared with the previous normal state, and is not related to acute events;
2. After adjustment for age, gender, and years of education, the standard cognitive test is normal, or the diagnostic criteria for MCI are not met;
3. Selected candidates can sign the informed consent form themselves.
Exclusion Criteria:
* (a) Aged under 45 years or older than 85 years; (b) Vascular dementia or other central nervous system diseases; (c) Hachinski Ischemic Scale score \> 4 points; (d); Unable to complete neuropsychological tests (e.g., blindness, deafness, severe language impairment); (e) Drug abuse or alcohol dependency within the last 6 months; (f) Current participation in other cognition studies; (g) Severe diabetes mellitus, or severe cardiovascular disease, cerebrovascular disease, liver diseases, kidney diseases, psychiatric disorders; (h) Contraindications to imaging techniques: claustrophobia, metallic implants (e.g., intracranial metal clips), electronic devices (e.g., cardiac pacemakers)
Primary outcome measure(s)
Incidence of Mild Cognitive Impairment (MCI) — through study completion, an average of 1 year Incidence of Mild Cognitive Impairment (MCI)
Incidence of Alzheimer's disease (AD) — through study completion, an average of 1 year Incidence of Alzheimer's disease (AD)
Trial sites (1)
Facility
City
Region
Status
The First Affiliated Hospital of Nanjing Medical University
Nanjing
China, Jiangsu
Recruiting
More The First Affiliated Hospital with Nanjing Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.